City of Hope Medical Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, City of Hope Medical Center sits in the top decile of US sponsors by registered trial count (#59 of 15,742 sponsors by registered trial count).
City of Hope Medical Center: 582 sponsored US clinical trials, 167 recruiting.
City of Hope Medical Center sponsors 582 registered US clinical trials on ClinicalTrials.gov, 167 of them currently recruiting, and 217 completed. 9 of these trials are in Phase 3-4 (later-stage) and 382 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 22 trials.
Top-decile sponsor footprint
City of Hope Medical Center ranks in the top decile of sponsors by registered trial count (#59 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
217 of 245 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
582 total, page 7 of 12
Long Term Follow-Up in Patients With Stage 0-IIIC Breast Cancer
NCT04661982
Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome
NCT01441687
Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life
NCT01030250
Long-Term Follow-Up in Patients With Prostate Cancer After Surgery
NCT03035500
Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
NCT00576979
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer
NCT00609791
Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery
NCT00977457
Assessment Tool for Older Patients With Cancer
NCT00477958
Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies
NCT00544466
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
NCT00544830
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
NCT00295893
Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen
NCT00706420
Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease
NCT00080756
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
NCT00641381
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
NCT07582172
The High Fiber Program to Increase Fiber Intake Among Patients Undergoing Allogeneic Hematopoietic Cell Transplant
NCT07664670
Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma
NCT07691450
Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care
NCT07690852
Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy
NCT07628894
Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT07578077
Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE Trial
NCT07590583
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07582159
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
NCT07583810
64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer
NCT07608627
BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
NCT07583303
Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
NCT07578025
Physiatry-Led Cancer Prehabilitation During Neoadjuvant Systemic Therapy to Improve Function in Stage III-IVA Gynecologic Cancer Patients
NCT07608445
Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers
NCT07611370
A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
NCT07619599
A Wearable Biosensor Patch for Non-Invasive Monitoring for Patients Undergoing Abdominal or Chest Surgery
NCT07612085
RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
NCT07218692
Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer
NCT07363408
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
NCT07271355
Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
NCT07608458
Autologous CD6-CAR Treg Cells for Patients With Stage 3 Type 1 Diabetes
NCT07395050
Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation
NCT07235501
Exercise and Mortality in Middle-Aged and Older Adults
NCT07224659
Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.
NCT07224737
Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting
NCT07224802
An Exosomal miRNA-based Liquid Biopsy for ICC Detection
NCT07225452
Impact of the Therapeutic Alliance on Reduction of Disparities in Latino End-of-Life Cancer Care
NCT04342611
Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)
NCT06381648
Early-Onset Colorectal Cancer Recurrence
NCT06271980
A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma
NCT06381583
Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer
NCT06654622
Predicting Local and Distant Recurrence in T1 Colorectal Cancer
NCT06314971
Stomach Cancer Exosome-based Detection
NCT06342427
Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial
NCT05205512
64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy
NCT03542695
Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors
NCT05142371
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 240 |
| Phase 2 | 142 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the City of Hope Medical Center pipeline
167 recruiting of 582 indexed (29% open); 217 completed (37%).
Phase mix: 9 late (III/IV) vs 382 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (22 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
City of Hope Medical Center: open-pipeline peers nationwide
Peers matched on 582 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
City of Hope Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 582 trials (± recruiting share)
- Bayer · 591 trials · 4% recruiting
- Janssen Research & Development · 593 trials · 11% recruiting
- Children's Hospital Medical Center, Cincinnati · 571 trials · 19% recruiting
- National Institute of Neurological Disorders and Stroke (NINDS) · 567 trials · 8% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Methodist Health System · 29% recruiting · 125 trials
- 89bio · 29% recruiting · 7 trials
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
Related
What to do with this City of Hope Medical Center page
582 registered trials is a research-attention snapshot, not an endorsement of City of Hope Medical Center or any single study.
- 167 of City of Hope Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition City of Hope Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. City of Hope Medical Center pipeline card: 582 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.